Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring [2]

AIDS

Volumn 17, Issue 7, 2003, Pages 1107-1108

  Boffito, Marta ^a,b   Back, David J ^a   Hoggard, Patrick G ^a   Caci, Annamaria ^b   Bonora, Stefano ^b   Raiteri, Riccardo ^b   Sinicco, Alessandro ^b   Reynolds, Helen E ^a   Khoo, Saye ^a   Di Perri, Giovanni ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MONITORING; ENVIRONMENTAL FACTOR; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRA INDIVIDUAL VARIABILITY; LETTER; LYMPHOCYTE COUNT; MALE; MASS SPECTROMETRY; NONHUMAN; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED KINGDOM; UNIVERSITY; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES;

EID: 0038216709     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305020-00029     Document Type: Letter

References (7)

1. Back DJ, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, et al. Therapeutic drug monitoring of HIV infection: current status and future directions. AIDS 2002; 16:S5-S37.
2. Marzolini C, Buclin T, Decosterd LA, Biollaz J, Telenti A. Nelfinavir plasma levels under twice daily and three-times daily regimens: high interpatient and low intrapatient variability. Ther Drug Monit 2001; 23:394-398.
3. Luber AD, Gunawan S, Lee S, Aquino G, Chaturvedi P, Scarsella A. Serum and plasma drug levels of amprenavir display limited inter- and intra-patient variability. In 5th International Congress on Drug Therapy in HIV Infection. Glasgow, October 2000 [Abstract P267].
4. Huitema ADR, van Heeswijk RPG, Veldkamp AI, Mulder JW, Meenhorst PL, Lange JMA, Beijnen JH. Population pharmacokinetics of saquinavir and ritonavir when used in combination in an unselected cohort of HIV-infected patients. In: 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, April 2001 [Abstract 3.4].
5. Zhou XJ, Havlir DV, Richman DD, Acosta EP, Hirsch M, Collier AC, et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-infected patients. AIDS 2000; 14:2869-2876.
6. Reynolds HE, Tjia JF, Gibbons SE, Khoo SH, Back DJ. Simultaneous determination of four HIV protease inhibitors by HPLC-MS/MS for use in a therapeutic drug monitoring service. Br J Clin Pharmacol 2001; 52:481P.
7. Hurst M, Faulds D. Lopinavir. Drugs 2000; 60:1371-1379.